Apogee strengthens case for longer-lasting eczema drug

BioPharma Dive

Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when administered once every three or six months.

Clinical Data Immunology & Inflammation Read full story